Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)-Reference-Cited by-同舟云学术

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)

Published:2020-09 Issue: Volume:137 Page:81-92
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Kurreck Annika,Heinemann Volker,Fischer von Weikersthal Ludwig,Decker Thomas,Kaiser Florian,Uhlig Jens,Schenk Michael,Freiberg-Richter Jens,Peuser Bettina,Denzlinger Claudio,Graeven Ullrich,Schwaner Ingo,Stahler Arndt,Heinrich Kathrin,Jung Andreas,Held Swantje,von Einem Jobst C.,Stintzing Sebastian,Giessen-Jung Clemens,Modest Dominik P.

Funder

Roche

Ludwig-Maximilians-Universität München

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Cancer treatment and survivorship statistics, 2014;DeSantis;CA Cancer J Clin,2014

2. The cancer survival gap between elderly and middle-aged patients in Europe is widening;Quaglia;Eur J Canc,2009

3. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials;Arnold;Ann Oncol,2017

4. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials;Holch;Eur J Canc,2017

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA);Cancers;2024-04-16

2. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G);The Oncologist;2023-11-10

3. A prediction model for in-hospital mortality in intensive care unit patients with metastatic cancer;Frontiers in Surgery;2023-01-30

4. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110);European Journal of Cancer;2022-09

5. Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group;Clinical Colorectal Cancer;2021-09